CSIMarket


Aytu Biopharma Inc   (AYTU)
Other Ticker:  
 

Aytu Biopharma Inc

AYTU's Fundamental analysis








Aytu Biopharma Inc 's sales fell by -15.51 % in II. Quarter 2023 from the same quarter a year ago. Ranking at No. 993

Major Pharmaceutical Preparations industry recorded deterioration of revenues by

Aytu Biopharma Inc net loss deacreased by in II. Quarter 2023 year on year, Aytu Biopharma Inc net loss increased by -96.71 % in II. Quarter 2023 year on year,

More on AYTU's Growth


Aytu Biopharma Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 549.8 in trailing twelve-month period.
Company
-
PE TTM   
Industry
360.97
PE TTM    
Company's Price to Sales ratio is at 0.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.


More on AYTU's Valuation
 
 Total Debt (Millions $) 16
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 4,834,250
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 3.16
 Tangible Book Value (Per Share $) -4.14

Aytu Biopharma Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 549.8 in trailing twelve-month period.
Company
-
PE TTM   
Industry
360.97
PE TTM    
Company's Price to Sales ratio is at 0.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.

Aytu Biopharma Inc Price to Book Ratio is at 0.47 lower than Indusry Avg. of 1523.92. and higher than S&P 500 Avg. of 0.01

More on AYTU's Valuation

  Market Capitalization (Millions $) 15
  Shares Outstanding (Millions) 6
  Employees 20
  Revenues (TTM) (Millions $) 97
  Net Income (TTM) (Millions $) -18
  Cash Flow (TTM) (Millions $) 0
  Capital Exp. (TTM) (Millions $) -
  Total Debt (Millions $) 16
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 4,834,250
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 3.16
  Tangible Book Value (Per Share $) -4.14

  Market Capitalization (Millions $) 15
  Shares Outstanding (Millions) 6
  Employees 20
  Revenues (TTM) (Millions $) 97
  Net Income (TTM) (Millions $) -18
  Cash Flow (TTM) (Millions $) 0
  Capital Exp. (TTM) (Millions $) -


    AYTU's Profitability Comparisons
Aytu Biopharma Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2023 to 10.65 %.







  Ratio
   Capital Ratio (MRQ) 1.11
  Total Debt to Equity (MRQ) 0.49
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.71
  Inventory Turnover Ratio (TTM) 2.67



Aytu Biopharma Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2023 to 10.65 %.



More on AYTU's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com